[{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Dosed in Phase I Clinical Study with Eye-Drop Formulation of Laquinimod\u00a0\u00a0","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Active Biotech Strengthens the Patent Protection for Laquinimod in Eye Disorders","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I"},{"orgOrder":0,"company":"Famar","sponsor":"Active Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Active Biotech Enters into a Manufacturing Agreement with Famar Health Care Services for New Formulation of Laquinimod","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"GREECE","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals for Laquinimod
Through the agreement, Active Biotech will get the material for the clinical development of the eye-drop formulation of ABR-215062 (laquinimod), which is used for the treatment of non-infectious non-anterior uveitis.
Laquinimod is a first-in-class immunomodulator that induces immune tolerance and reduces the pro-inflammatory and angiogenic response by targeting of the myeloid cell compartment.
A preclinical program shows that the laquinimod eye-drop is safe and well tolerated, and the safety of this new formulation will now be tested in a phase I clinical study in healthy subjects.